[Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].
The evidence of sorbitol excess in the crystalline lens of alloxan-diabetic rats has led to anticipate the role of the enzyme aldose-reductase in the pathogenesis of the diabetic cataract. In addition, a number of experimental works have more recently shown the involvement of myoinositol deficiency, which probably results from the sorbitol accumulation. These metabolic pathways are most likely implicated in the pathogenesis of diabetic neuropathy and perhaps additionally in that of microangiopathy. The synthesis of several aldose-reductase inhibitors (AR inhibitors) confirmed experimentally these hypothesis. By reducing the activity of the enzyme aldose-reductase, these substances suppress the adverse metabolic consequences of polyol accumulation, myositol deficiency and dysfunction of the Na+/K+ ATPase dependent sodium activity. Although different experimentations showed that the AR inhibitors could prevent in animals the development of experimental cataract as well as the early functional or later anatomic abnormalities of the diabetic retinopathy and nephropathy, the clinical trials did not clearly support these experimental results in humans. On the other hand, the AR inhibitors were proved to exhibit some efficacy in the early stage of diabetic neuropathy and in incipient nephropathy where they delay the development of albustix positive proteinuria. However, the benefit of an early treatment with AR inhibitors should be confirmed by long term prospective studies, which could also assess the safety of these drugs in chronic administration.
Brogard
J M
JM
Service de Médecine Interne de la Clinique Médicale B, Centre Hospitalo-Universitaire de Strasbourg.
Caro-Sampara
F
F
Blicklé
J F
JF
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002386:Cataract / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D005690:Galactose; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D048289:Imidazolidines; D007294:Inositol / Q000172:deficiency; D007546:Isoquinolines / Q000627:therapeutic use; D007908:Lens, Crystalline / Q000378:metabolism; D009281:Naphthalenes / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D051381:Rats; D013402:Sugar Alcohols / Q000378:metabolism*
D007093:Imidazoles; D048289:Imidazolidines; D007546:Isoquinolines; D009281:Naphthalenes; D010276:Parasympatholytics; D013402:Sugar Alcohols; C040550:tolrestat; D007294:Inositol; C016212:alrestatin; D000449:Aldehyde Reductase; C026411:sorbinil; D005690:Galactose
Le rôle des polyols dans le développement des complications du diabète. Intérêt des inhibiteurs de l'aldose-réductase.